Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy
Aim The study investigated the value of faecal lactoferrin as a follow‐up biomarker for mucosal healing of ulcerative colitis during granulocyte and monocyte adsorptive apheresis (GMA) therapy. Method Patients with ulcerative colitis exhibiting a moderate or severe disease activity with a partial Ma...
Gespeichert in:
| Veröffentlicht in: | Colorectal disease 2016-07, Vol.18 (7), p.696-702 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 702 |
|---|---|
| container_issue | 7 |
| container_start_page | 696 |
| container_title | Colorectal disease |
| container_volume | 18 |
| creator | Sagawa, T. Kakizaki, S. Tomizawa, T. Nakayama, T. Tanaka, H. Tojima, H. Sato, K. Kusano, M. Okamura, S. Yamada, M. |
| description | Aim
The study investigated the value of faecal lactoferrin as a follow‐up biomarker for mucosal healing of ulcerative colitis during granulocyte and monocyte adsorptive apheresis (GMA) therapy.
Method
Patients with ulcerative colitis exhibiting a moderate or severe disease activity with a partial Mayo Score (pMS) of over 4 were enrolled in this study. The patients received 10 courses of GMA therapy. The pMS value and faecal lactoferrin level were monitored and compared with the findings of endoscopy until 12 months after the last dose of GMA therapy.
Results
Twenty patients (male:female 11:9) were enrolled in this study. Twelve had total colitis, while six had left‐sided involvement and two had distal proctitis. Thirteen (65.0%) responded to GMA therapy. The faecal lactoferrin levels were significantly decreased in patients who responded to GMA therapy (P |
| doi_str_mv | 10.1111/codi.13258 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808696633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1808696633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4008-170e89abeb128576aa8ce177498bc3fcf2a3eca9b1341b7ef764256bd74645ad3</originalsourceid><addsrcrecordid>eNqNkctu1DAUhiMEojc2PADyEiGl-MSJ7SzRQIdKVYsQpUvLcU46BidO7YR2HoZ3refSLhHe-Nj6_k-y_yx7C_QU0vpofGtPgRWVfJEdQslZDgzky-1c5LIGepAdxfiLUuAC5OvsoOCilFXFDrO_ZxqNdsRpM_kOQ7ADsZFoMkfsZkca63sdfmMgnQ-kn42PiV6hdna4JQke9WRxmCK5t9OKzM5gSDd_kBjv7JRU7Rw26G3Qw-y8WU9I9NCS3g_7Qxt9GLcRPa4wYEyhKQ16XJ9krzrtIr7Z78fZ9dmXH4uv-cXV8nzx6SI3JaUyB0FR1rrBBgpZCa61NAhClLVsDOtMV2iWXlk3wEpoBHaCl0XFm1aUvKx0y46z9zvvGPzdjHFSvY0GndMD-jkqkFTymnPG_gcFySkHkdAPO9QEH2PATo3Bpt9cK6Bq05zaNKe2zSX43d47Nz22z-hTVQmAHXBvHa7_oVKLq8_nT9J8l7FxwofnTCpUccFEpW4ul-p7KZffFuynumGPgjS20g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1801860617</pqid></control><display><type>article</type><title>Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Sagawa, T. ; Kakizaki, S. ; Tomizawa, T. ; Nakayama, T. ; Tanaka, H. ; Tojima, H. ; Sato, K. ; Kusano, M. ; Okamura, S. ; Yamada, M.</creator><creatorcontrib>Sagawa, T. ; Kakizaki, S. ; Tomizawa, T. ; Nakayama, T. ; Tanaka, H. ; Tojima, H. ; Sato, K. ; Kusano, M. ; Okamura, S. ; Yamada, M.</creatorcontrib><description>Aim
The study investigated the value of faecal lactoferrin as a follow‐up biomarker for mucosal healing of ulcerative colitis during granulocyte and monocyte adsorptive apheresis (GMA) therapy.
Method
Patients with ulcerative colitis exhibiting a moderate or severe disease activity with a partial Mayo Score (pMS) of over 4 were enrolled in this study. The patients received 10 courses of GMA therapy. The pMS value and faecal lactoferrin level were monitored and compared with the findings of endoscopy until 12 months after the last dose of GMA therapy.
Results
Twenty patients (male:female 11:9) were enrolled in this study. Twelve had total colitis, while six had left‐sided involvement and two had distal proctitis. Thirteen (65.0%) responded to GMA therapy. The faecal lactoferrin levels were significantly decreased in patients who responded to GMA therapy (P < 0.05), whereas the levels did not change in non‐responders. Moreover, the faecal lactoferrin levels correlated with the endoscopic findings (r = 0.792, P < 0.01) and pMS scores (r = 0.529, P < 0.01). The correlation coefficients between the faecal lactoferrin levels and mucosal findings were higher than those observed between the pMS score and mucosal findings.
Conclusion
The faecal lactoferrin level is a useful biomarker of the mucosal findings in ulcerative colitis. Although endoscopy is the gold standard, the faecal lactoferrin level can be used as a biomarker during GMA therapy in patients with ulcerative colitis.</description><identifier>ISSN: 1462-8910</identifier><identifier>EISSN: 1463-1318</identifier><identifier>DOI: 10.1111/codi.13258</identifier><identifier>PMID: 26748553</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; biomarker ; Biomarkers - analysis ; Colitis, Ulcerative - pathology ; Colitis, Ulcerative - therapy ; Faecal lactoferrin ; Feces - chemistry ; Female ; granulocyte and monocyte adsorptive apheresis ; Granulocytes ; Humans ; Intestinal Mucosa - pathology ; Lactoferrin - analysis ; Leukapheresis - methods ; Male ; Middle Aged ; Monocytes ; mucosal healing ; Treatment Outcome ; ulcerative colitis ; Young Adult</subject><ispartof>Colorectal disease, 2016-07, Vol.18 (7), p.696-702</ispartof><rights>Colorectal Disease © 2016 The Association of Coloproctology of Great Britain and Ireland</rights><rights>Colorectal Disease © 2016 The Association of Coloproctology of Great Britain and Ireland.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4008-170e89abeb128576aa8ce177498bc3fcf2a3eca9b1341b7ef764256bd74645ad3</citedby><cites>FETCH-LOGICAL-c4008-170e89abeb128576aa8ce177498bc3fcf2a3eca9b1341b7ef764256bd74645ad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcodi.13258$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcodi.13258$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26748553$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sagawa, T.</creatorcontrib><creatorcontrib>Kakizaki, S.</creatorcontrib><creatorcontrib>Tomizawa, T.</creatorcontrib><creatorcontrib>Nakayama, T.</creatorcontrib><creatorcontrib>Tanaka, H.</creatorcontrib><creatorcontrib>Tojima, H.</creatorcontrib><creatorcontrib>Sato, K.</creatorcontrib><creatorcontrib>Kusano, M.</creatorcontrib><creatorcontrib>Okamura, S.</creatorcontrib><creatorcontrib>Yamada, M.</creatorcontrib><title>Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy</title><title>Colorectal disease</title><addtitle>Colorectal Dis</addtitle><description>Aim
The study investigated the value of faecal lactoferrin as a follow‐up biomarker for mucosal healing of ulcerative colitis during granulocyte and monocyte adsorptive apheresis (GMA) therapy.
Method
Patients with ulcerative colitis exhibiting a moderate or severe disease activity with a partial Mayo Score (pMS) of over 4 were enrolled in this study. The patients received 10 courses of GMA therapy. The pMS value and faecal lactoferrin level were monitored and compared with the findings of endoscopy until 12 months after the last dose of GMA therapy.
Results
Twenty patients (male:female 11:9) were enrolled in this study. Twelve had total colitis, while six had left‐sided involvement and two had distal proctitis. Thirteen (65.0%) responded to GMA therapy. The faecal lactoferrin levels were significantly decreased in patients who responded to GMA therapy (P < 0.05), whereas the levels did not change in non‐responders. Moreover, the faecal lactoferrin levels correlated with the endoscopic findings (r = 0.792, P < 0.01) and pMS scores (r = 0.529, P < 0.01). The correlation coefficients between the faecal lactoferrin levels and mucosal findings were higher than those observed between the pMS score and mucosal findings.
Conclusion
The faecal lactoferrin level is a useful biomarker of the mucosal findings in ulcerative colitis. Although endoscopy is the gold standard, the faecal lactoferrin level can be used as a biomarker during GMA therapy in patients with ulcerative colitis.</description><subject>Adult</subject><subject>Aged</subject><subject>biomarker</subject><subject>Biomarkers - analysis</subject><subject>Colitis, Ulcerative - pathology</subject><subject>Colitis, Ulcerative - therapy</subject><subject>Faecal lactoferrin</subject><subject>Feces - chemistry</subject><subject>Female</subject><subject>granulocyte and monocyte adsorptive apheresis</subject><subject>Granulocytes</subject><subject>Humans</subject><subject>Intestinal Mucosa - pathology</subject><subject>Lactoferrin - analysis</subject><subject>Leukapheresis - methods</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monocytes</subject><subject>mucosal healing</subject><subject>Treatment Outcome</subject><subject>ulcerative colitis</subject><subject>Young Adult</subject><issn>1462-8910</issn><issn>1463-1318</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctu1DAUhiMEojc2PADyEiGl-MSJ7SzRQIdKVYsQpUvLcU46BidO7YR2HoZ3refSLhHe-Nj6_k-y_yx7C_QU0vpofGtPgRWVfJEdQslZDgzky-1c5LIGepAdxfiLUuAC5OvsoOCilFXFDrO_ZxqNdsRpM_kOQ7ADsZFoMkfsZkca63sdfmMgnQ-kn42PiV6hdna4JQke9WRxmCK5t9OKzM5gSDd_kBjv7JRU7Rw26G3Qw-y8WU9I9NCS3g_7Qxt9GLcRPa4wYEyhKQ16XJ9krzrtIr7Z78fZ9dmXH4uv-cXV8nzx6SI3JaUyB0FR1rrBBgpZCa61NAhClLVsDOtMV2iWXlk3wEpoBHaCl0XFm1aUvKx0y46z9zvvGPzdjHFSvY0GndMD-jkqkFTymnPG_gcFySkHkdAPO9QEH2PATo3Bpt9cK6Bq05zaNKe2zSX43d47Nz22z-hTVQmAHXBvHa7_oVKLq8_nT9J8l7FxwofnTCpUccFEpW4ul-p7KZffFuynumGPgjS20g</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>Sagawa, T.</creator><creator>Kakizaki, S.</creator><creator>Tomizawa, T.</creator><creator>Nakayama, T.</creator><creator>Tanaka, H.</creator><creator>Tojima, H.</creator><creator>Sato, K.</creator><creator>Kusano, M.</creator><creator>Okamura, S.</creator><creator>Yamada, M.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201607</creationdate><title>Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy</title><author>Sagawa, T. ; Kakizaki, S. ; Tomizawa, T. ; Nakayama, T. ; Tanaka, H. ; Tojima, H. ; Sato, K. ; Kusano, M. ; Okamura, S. ; Yamada, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4008-170e89abeb128576aa8ce177498bc3fcf2a3eca9b1341b7ef764256bd74645ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>biomarker</topic><topic>Biomarkers - analysis</topic><topic>Colitis, Ulcerative - pathology</topic><topic>Colitis, Ulcerative - therapy</topic><topic>Faecal lactoferrin</topic><topic>Feces - chemistry</topic><topic>Female</topic><topic>granulocyte and monocyte adsorptive apheresis</topic><topic>Granulocytes</topic><topic>Humans</topic><topic>Intestinal Mucosa - pathology</topic><topic>Lactoferrin - analysis</topic><topic>Leukapheresis - methods</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monocytes</topic><topic>mucosal healing</topic><topic>Treatment Outcome</topic><topic>ulcerative colitis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sagawa, T.</creatorcontrib><creatorcontrib>Kakizaki, S.</creatorcontrib><creatorcontrib>Tomizawa, T.</creatorcontrib><creatorcontrib>Nakayama, T.</creatorcontrib><creatorcontrib>Tanaka, H.</creatorcontrib><creatorcontrib>Tojima, H.</creatorcontrib><creatorcontrib>Sato, K.</creatorcontrib><creatorcontrib>Kusano, M.</creatorcontrib><creatorcontrib>Okamura, S.</creatorcontrib><creatorcontrib>Yamada, M.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Colorectal disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sagawa, T.</au><au>Kakizaki, S.</au><au>Tomizawa, T.</au><au>Nakayama, T.</au><au>Tanaka, H.</au><au>Tojima, H.</au><au>Sato, K.</au><au>Kusano, M.</au><au>Okamura, S.</au><au>Yamada, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy</atitle><jtitle>Colorectal disease</jtitle><addtitle>Colorectal Dis</addtitle><date>2016-07</date><risdate>2016</risdate><volume>18</volume><issue>7</issue><spage>696</spage><epage>702</epage><pages>696-702</pages><issn>1462-8910</issn><eissn>1463-1318</eissn><abstract>Aim
The study investigated the value of faecal lactoferrin as a follow‐up biomarker for mucosal healing of ulcerative colitis during granulocyte and monocyte adsorptive apheresis (GMA) therapy.
Method
Patients with ulcerative colitis exhibiting a moderate or severe disease activity with a partial Mayo Score (pMS) of over 4 were enrolled in this study. The patients received 10 courses of GMA therapy. The pMS value and faecal lactoferrin level were monitored and compared with the findings of endoscopy until 12 months after the last dose of GMA therapy.
Results
Twenty patients (male:female 11:9) were enrolled in this study. Twelve had total colitis, while six had left‐sided involvement and two had distal proctitis. Thirteen (65.0%) responded to GMA therapy. The faecal lactoferrin levels were significantly decreased in patients who responded to GMA therapy (P < 0.05), whereas the levels did not change in non‐responders. Moreover, the faecal lactoferrin levels correlated with the endoscopic findings (r = 0.792, P < 0.01) and pMS scores (r = 0.529, P < 0.01). The correlation coefficients between the faecal lactoferrin levels and mucosal findings were higher than those observed between the pMS score and mucosal findings.
Conclusion
The faecal lactoferrin level is a useful biomarker of the mucosal findings in ulcerative colitis. Although endoscopy is the gold standard, the faecal lactoferrin level can be used as a biomarker during GMA therapy in patients with ulcerative colitis.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>26748553</pmid><doi>10.1111/codi.13258</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8910 |
| ispartof | Colorectal disease, 2016-07, Vol.18 (7), p.696-702 |
| issn | 1462-8910 1463-1318 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1808696633 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged biomarker Biomarkers - analysis Colitis, Ulcerative - pathology Colitis, Ulcerative - therapy Faecal lactoferrin Feces - chemistry Female granulocyte and monocyte adsorptive apheresis Granulocytes Humans Intestinal Mucosa - pathology Lactoferrin - analysis Leukapheresis - methods Male Middle Aged Monocytes mucosal healing Treatment Outcome ulcerative colitis Young Adult |
| title | Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T17%3A29%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Faecal%20lactoferrin%20is%20a%20useful%20biomarker%20for%20mucosal%20healing%20in%20patients%20with%20ulcerative%20colitis%20during%20granulocyte%20and%20monocyte%20adsorptive%20apheresis%20therapy&rft.jtitle=Colorectal%20disease&rft.au=Sagawa,%20T.&rft.date=2016-07&rft.volume=18&rft.issue=7&rft.spage=696&rft.epage=702&rft.pages=696-702&rft.issn=1462-8910&rft.eissn=1463-1318&rft_id=info:doi/10.1111/codi.13258&rft_dat=%3Cproquest_cross%3E1808696633%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1801860617&rft_id=info:pmid/26748553&rfr_iscdi=true |